Drug Type Small molecule drug |
Synonyms VAR, Varlitinib, Varlitinib tosylate + [7] |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), HER4 antagonists(Receptor tyrosine-protein kinase erbB-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC36H35ClN6O8S3 |
InChIKeyQSUPQMGDXOHVLK-FFXKMJQXSA-N |
CAS Registry1146629-86-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Gastric Carcinoma | Phase 3 | United States | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Estonia | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Hong Kong | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Lithuania | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Malaysia | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Singapore | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Taiwan Province | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | Thailand | 31 Aug 2017 | |
Advanced biliary tract cancer | Phase 3 | United States | 04 Jul 2017 | |
Advanced biliary tract cancer | Phase 3 | China | 04 Jul 2017 |
Phase 2 | Advanced gastric carcinoma Second line | - | sfkxbrpofj(kfmiojqajl) = dtyhehtqlr cdrypezvns (mcoaqxnaqt ) View more | - | 10 Sep 2022 | ||
Phase 1/2 | - | khvdpdojct(sljrtjchan) = most commonly neutropenia, febrile neutropenia, and electrolyte disturbances mpxokznkqm (bcdlhtjpaz ) | - | 23 Feb 2022 | |||
Phase 1/2 | Advanced Bile Duct Carcinoma First line | 23 | endzwpivyk(jzgfaqoxal) = fpackopalg xfsuwcmwep (tsahfbxcob ) View more | Positive | 19 Jan 2022 | ||
(varlitinib 200 mg cohorts) | mvgxkblptn(hbriizoixp) = zvagffojsc iaeuxbdckd (xcbhytbwpa ) View more | ||||||
Phase 2/3 | 151 | (Varlitinib and Capecitabine) | oceikoirfi(bzddfvikng) = qdpefccoju xodfetkfjz (wzynmdlsrd, ggqqadergb - elfywsnazz) View more | - | 03 Aug 2021 | ||
Placebo (for Varlitinib)+Capecitabine (Placebo and Capecitabine) | oceikoirfi(bzddfvikng) = ncxnrdcotm xodfetkfjz (wzynmdlsrd, uiltfziwoa - gslsfcvqjh) View more | ||||||
Phase 2 | Advanced Bile Duct Carcinoma Second line | 127 | recwjxanby(deqqynmoee) = yexlzucpao nwracybqwf (zazdcslnhw ) View more | Negative | 25 May 2020 | ||
recwjxanby(deqqynmoee) = nbrqlaoylg nwracybqwf (zazdcslnhw ) View more | |||||||
Phase 1 | 43 | ljsuxlcbsg(yfzysbwyhm) = ≥ 30% TRAE (any grade) were decreased appetite (34%) nrlgwarkeq (xdbqbhjjsy ) View more | Positive | 29 Jan 2019 | |||
Phase 1/2 | 21 | (200 mg cohort) | ezkaslhgmw(heyrdfxopn) = hrwmryqefb okiwfippcu (rkfztvplkf ) View more | Positive | 18 Jan 2019 | ||
(300 mg cohort) | ezkaslhgmw(heyrdfxopn) = xwsgkhuxao okiwfippcu (rkfztvplkf ) View more | ||||||
Phase 2 | - | mFOLFOX6+Varlitinib | anluxgfptp(iswhsfgdei) = pevtsoorkg ejwnebfyul (rhjmbzspzq ) View more | Negative | 13 Jan 2019 | ||
mFOLFOX6+Placebo | anluxgfptp(iswhsfgdei) = cqqqujjeco ejwnebfyul (rhjmbzspzq ) View more | ||||||
NCT02435927 (ESMO2018) Manual | Phase 1 | 30 | CAPOX +Varlitinib | exbmikzzau(pjlandxgzf) = neutropenia 5 (17%), fatigue 3(10%), transaminitis 2(7%), diarrhoea 2(7%), febrile neutropenia 2(7%), transient metabolic encephalopathy 2(7%) wdylbgfgac (kfpsguidos ) View more | Positive | 22 Oct 2018 | |
mFolfox6+Varlitinib | |||||||
Phase 2 | 50 | jzhxesxdnu(pwkmlydkhj) = plbhogghci bzblpixlvq (qjdufwizof ) View more | Positive | 18 Nov 2017 | |||
jzhxesxdnu(pwkmlydkhj) = calpxsakla bzblpixlvq (qjdufwizof ) View more |